Search

Your search keyword '"Paolo Grossi"' showing total 10 results
Start Over Author "Paolo Grossi" Publisher hal ccsd
10 results on '"Paolo Grossi"'

1. Direct‐Acting Antivirals in Hepatitis C Virus‐Associated Diffuse Large B‐cell Lymphomas

Author

Maria Grazia Rumi, Laurent Alric, Francesco Passamonti, Dario Marino, Virginia Valeria Ferretti, Isabel Cano, Michele Merli, Manuel Gotti, Roberta Sciarra, Maria Chiara Tisi, Paolo Grossi, Véronique Loustaud-Ratti, Angela Ferrari, Alice Di Rocco, Carlo Visco, Maria Goldaniga, Chiara Rusconi, Emanuele Cencini, F. Benanti, Antonello Sica, Massimo Gentile, Marco Frigeni, Luca Arcaini, Lucia Farina, Francesco Piazza, Annalisa Arcari, Valentina Zuccaro, Lara Mannelli, Caroline Besson, Mario Pirisi, Universitá degli Studi dell’Insubria = University of Insubria [Varese] (Uninsubria), Università degli Studi di Pavia = University of Pavia (UNIPV), Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Ospedale San Bortolo, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Azienda Ospedaliera Careggi, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Azienda Unita` Sanitaria Locale, Azienda Unita` Sanitaria Locale, La Spezia, IRCCS Istituto Nazionale dei Tumori [Milano], University of Piemonte Orientale, Partenaires INRAE, Università degli Studi di Padova = University of Padua (Unipd), Université de Limoges (UNILIM), Azienda Unità Sanitaria Locale di Bologna (AUSL), Veneto Institute of Oncology, IOV - IRCCS, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Ospedale Niguarda Ca' Granda Hospital, Università degli Studi di Siena = University of Siena (UNISI), University of Catania [Italy], Università degli Studi di Milano = University of Milan (UNIMI), Fondazione IRCCS Policlinico San Matteo, Service d’Hématologie et d’Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France, Pagès, Nathalie, University of Insubria, Varese, University of Pavia, Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Institut de Recherche pour le Développement (IRD), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], University of Padova [Padova, Italy], University of Siena (University of Siena), University of Milan, Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), and Université de Toulouse (UT)

Subjects
Male, Cancer Research, Sofosbuvir, Diffuse large B‐cell lymphoma, Hematologic Malignancies, [SDV]Life Sciences [q-bio], Direct‐acting antivirals, Hepatitis C virus, R‐CHOP, Hepacivirus, Direct-acting antivirals, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, 030212 general & internal medicine, Aged, 80 and over, Dasabuvir, Incidence, Hepatitis C, Diffuse large B-cell lymphoma, Middle Aged, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, 3. Good health, [SDV] Life Sciences [q-bio], [SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences, Italy, Oncology, Vincristine, R-CHOP, 030220 oncology & carcinogenesis, Rituximab, Female, Lymphoma, Large B-Cell, Diffuse, medicine.drug, Ledipasvir, Adult, medicine.medical_specialty, Antiviral Agents, Disease-Free Survival, 03 medical and health sciences, Internal medicine, medicine, Humans, Progression-free survival, Cyclophosphamide, Aged, Retrospective Studies, business.industry, Ribavirin, Hepatitis C, Chronic, medicine.disease, chemistry, Paritaprevir, Doxorubicin, Prednisone, business
Abstract

International audience; Background: International guidelines suggest hepatitis C virus (HCV) eradication by direct-acting antivirals (DAAs) after first-line immunochemotherapy (I-CT) in patients with HCV-positive diffuse large B-cell lymphoma (DLBCL), although limited experiences substantiate this recommendation. Moreover, only a few data concerning concurrent administration of DAAs with I-CT have been reported.Subjects, materials, and methods: We analyzed hematological and virological outcome and survival of 47 consecutive patients with HCV-positive DLBCL treated at 23 Italian and French centers with DAAs either concurrently (concurrent cohort [ConC]: n = 9) or subsequently (sequential cohort [SeqC]: n = 38) to first-line I-CT (mainly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone [R-CHOP]-like).Results: Median age was 61 years, 89% of patients had stage III/IV, and 25% presented evidence of cirrhosis. Genotype was 1 in 56% and 2 in 34% of cases. Overall, 46 of 47 patients obtained complete response to I-CT. All patients received appropriate DAAs according to genotype, mainly sofosbuvir-based regimens (n = 45). Overall, 45 patients (96%) achieved sustained virological response, 8 of 9 in ConC and 37 of 38 in SeqC. DAAs were well tolerated, with only 11 patients experiencing grade 1-2 adverse events. Twenty-three patients experienced hepatic toxicity (grade 3-4 in seven) following I-CT in SeqC, compared to only one patient in ConC. At a median follow-up of 2.8 years, two patients died (2-year overall survival, 97.4%) and three progressed (2-year progression-free survival, 93.1%).Conclusion: Excellent outcome of this cohort of HCV-positive DLBCL suggests benefit of HCV eradication by DAAs either after or during I-CT. Moreover, concurrent DAAs and R-CHOP administration appeared feasible, effective, and ideally preferable to deferred administration of DAAs for the prevention of hepatic toxicity.Implications for practice: Hepatitis C virus (HCV)-associated diffuse large B-cell lymphomas (DLBCLs) represent a great therapeutic challenge, especially in terms of hepatic toxicity during immune-chemotherapy (I-CT) and long-term hepatic complications. The advent of highly effective and toxicity-free direct-acting antivirals (DAAs) created an exciting opportunity to easily eradicate HCV shortly after or in concomitance with first-line immunochemotherapy (usually R-CHOP). This retrospective international study reports the real-life use of the combination of these two therapeutic modalities either in the concurrent or sequential approach (DAAs after I-CT) in 47 patients. The favorable reported results on long-term outcome seem to support the eradication of HCV with DAAs in all patients with HCV-positive DLBCL. Moreover, the results from the concurrent approach were effective and safe and displayed an advantage in preventing hepatic toxicity during I-CT.

Published
2019
Full Text
View/download PDF

2. Validated Risk Score for Predicting 6-Month Mortality in Infective Endocarditis

Author

Lawrence P. Park, Vivian H. Chu, Gail Peterson, Athanasios Skoutelis, Tatjana Lejko‐Zupa, Emilio Bouza, Pierre Tattevin, Gilbert Habib, Ren Tan, Javier Gonzalez, Javier Altclas, Jameela Edathodu, Claudio Querido Fortes, Rinaldo Focaccia Siciliano, Orathai Pachirat, Souha Kanj, Andrew Wang, Liliana Clara, Marisa Sanchez, José Casabé, Claudia Cortes, Francisco Nacinovich, Pablo Fernandez Oses, Ricardo Ronderos, Adriana Sucari, Jorge Thierer, Silvia Kogan, Denis Spelman, Eugene Athan, Owen Harris, Karina Kennedy, David Gordon, Lito Papanicolas, Tony Korman, Despina Kotsanas, Robyn Dever, Phillip Jones, Pam Konecny, Richard Lawrence, David Rees, Suzanne Ryan, Michael P. Feneley, John Harkness, Jeffrey Post, Porl Reinbott, Rainer Gattringer, Franz Wiesbauer, Adriana Ribas Andrade, Ana Cláudia Passos de Brito, Armenio Costa Guimarães, Max Grinberg, Alfredo José Mansur, Tania Mara Varejao Strabelli, Marcelo Luiz Campos Vieira, Regina Aparecida de Medeiros Tranchesi, Marcelo Goulart Paiva, Auristela de Oliveira Ramos, Clara Weksler, Giovanna Ferraiuoli, Wilma Golebiovski, Cristiane Lamas, James A. Karlowsky, Yoav Keynan, Andrew M. Morris, Ethan Rubinstein, Sandra Braun Jones, Patricia Garcia, Alberto Fica, Rodrigo Montagna Mella, Ricardo Fernandez, Liliana Franco, Astrid Natalia Jaramillo, Bruno Barsic, Suzana Bukovski, Vladimir Krajinovic, Ana Pangercic, Igor Rudez, Josip Vincelj, Tomas Freiberger, Jiri Pol, Barbora Zaloudikova, Zainab Ashour, Amani El Kholy, Marwa Mishaal, Dina Osama, Hussien Rizk, Neijla Aissa, Corentine Alauzet, Francois Alla, Catherine Campagnac, Thanh Doco‐Lecompte, Christine Selton‐Suty, Jean‐Paul Casalta, Pierre‐Edouard Fournier, Didier Raoult, Franck Thuny, Francois Delahaye, Armelle Delahaye, Francois Vandenesch, Erwan Donal, Pierre Yves Donnio, Erwan Flecher, Christian Michelet, Matthieu Revest, Florent Chevalier, Antoine Jeu, Jean Paul Rémadi, Dan Rusinaru, Christophe Tribouilloy, Yvette Bernard, Catherine Chirouze, Bruno Hoen, Joel Leroy, Patrick Plesiat, Christoph Naber, Carl Neuerburg, Bahram Mazaheri, Sophia Athanasia, Ioannis Deliolanis, Helen Giamarellou, Tsaganos Thomas, Efthymia Giannitsioti, Elena Mylona, Olga Paniara, Konstantinos Papanicolaou, John Pyros, Konstantinos Papanikolaou, Gautam Sharma, Johnson Francis, Lathi Nair, Vinod Thomas, Krishnan Venugopal, Margaret M. Hannan, John P. Hurley, Amos Cahan, Dan Gilon, Sarah Israel, Maya Korem, Jacob Strahilevitz, Emanuele Durante‐Mangoni, Irene Mattucci, Daniela Pinto, Federica Agrusta, Alessandra Senese, Enrico Ragone, Riccardo Utili, Enrico Cecchi, Francesco De Rosa, Davide Forno, Massimo Imazio, Rita Trinchero, Paolo Grossi, Mariangela Lattanzio, Antonio Toniolo, Antonio Goglio, Annibale Raglio, Veronica Ravasio, Marco Rizzi, Fredy Suter, Giampiero Carosi, Silvia Magri, Liana Signorini, Zeina Kanafani, Souha S. Kanj, Ahmad Sharif‐Yakan, Imran Abidin, Syahidah Syed Tamin, Eduardo Rivera Martínez, Gabriel Israel Soto Nieto, Jan T.M. van der Meer, Stephen Chambers, David Holland, Arthur Morris, Nigel Raymond, Kerry Read, David R. Murdoch, Stefan Dragulescu, Adina Ionac, Cristian Mornos, O.M. Butkevich, Natalia Chipigina, Ozerecky Kirill, Kulichenko Vadim, Tatiana Vinogradova, Magid Halim, Yee‐Yun Liew, Ru‐San Tan, Mateja Logar, Manica Mueller‐Premru, Patrick Commerford, Anita Commerford, Eduan Deetlefs, Cass Hansa, Mpiko Ntsekhe, Manuel Almela, Yolanda Armero, Manuel Azqueta, Ximena Castañeda, Carlos Cervera, Carlos Falces, Cristina Garcia‐de‐la‐Maria, Guillermina Fita, Jose M. Gatell, Magda Heras, Jaime Llopis, Francesc Marco, Carlos A. Mestres, José M. Miró, Asuncion Moreno, Salvador Ninot, Carlos Paré, Juan M. Pericas, Jose Ramirez, Irene Rovira, Marta Sitges, Ignasi Anguera, Bernat Font, Joan Raimon Guma, Javier Bermejo, Miguel Angel Garcia Fernández, Victor Gonzalez‐Ramallo, Mercedes Marín, Patricia Muñoz, Miguel Pedromingo, Jorge Roda, Marta Rodríguez‐Créixems, Jorge Solis, Benito Almirante, Nuria Fernandez‐Hidalgo, Pilar Tornos, Arístides de Alarcón, Ricardo Parra, Eric Alestig, Magnus Johansson, Lars Olaison, Ulrika Snygg‐Martin, Pimchitra Pachirat, Burabha Pussadhamma, Vichai Senthong, Anna Casey, Tom Elliott, Peter Lambert, Richard Watkin, Christina Eyton, John L. Klein, Suzanne Bradley, Carol Kauffman, Roger Bedimo, G. Ralph Corey, Anna Lisa Crowley, Pamela Douglas, Laura Drew, Vance G. Fowler, Thomas Holland, Tahaniyat Lalani, Daniel Mudrick, Zaniab Samad, Daniel Sexton, Martin Stryjewski, Christopher W. Woods, Stamatios Lerakis, Robert Cantey, Lisa Steed, Dannah Wray, Stuart A. Dickerman, Hector Bonilla, Joseph DiPersio, Sara‐Jane Salstrom, John Baddley, Mukesh Patel, Amy Stancoven, Donald Levine, Jonathan Riddle, Michael Rybak, Christopher H. Cabell, Khaula Baloch, Christy C. Dixon, Tina Harding, Marian Jones‐Richmond, Bob Sanderford, Judy Stafford, Kevin Anstrom, Arnold S. Bayer, A. W. Karchmer, Daniel J. Sexton, Vivian Chu, David T. Durack, Susannah Eykyn, Phillipe Moreillon, Duke University Medical Center, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], Fonction, structure et inactivation d'ARN bactériens, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS), Service de cardiologie, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS), Jonchère, Laurent, Universitat de Barcelona, Mazaheri, Bahram (Beitragende*r), Naber, Christoph (Beitragende*r), and Neuerburg, Carl (Beitragende*r)

Subjects
Male, Infeccions quirúrgiques, Surgical wound infection, Medizin, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, 0302 clinical medicine, Risk Factors, Clinical Studies, Registries, 030212 general & internal medicine, Original Research, Framingham Risk Score, Endocarditis, Hazard ratio, Middle Aged, Prognosis, infection, mortality, prognosis, surgery, valves, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 3. Good health, Infective endocarditis, Cohort, Female, Mortality/Survival, Cardiology and Cardiovascular Medicine, Risk assessment, Infection, Cohort study, Adult, medicine.medical_specialty, Lower risk, Risk Assessment, Sensitivity and Specificity, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, Mortalitat, medicine, Humans, Infectious Endocarditis, Mortality, Propensity Score, Aged, Models, Statistical, Cirurgia, business.industry, Proportional hazards model, Reproducibility of Results, medicine.disease, Surgery, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Valvular Heart Disease, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business
Abstract

Background Host factors and complications have been associated with higher mortality in infective endocarditis ( IE ). We sought to develop and validate a model of clinical characteristics to predict 6‐month mortality in IE . Methods and Results Using a large multinational prospective registry of definite IE (International Collaboration on Endocarditis [ ICE ]–Prospective Cohort Study [ PCS ], 2000–2006, n=4049), a model to predict 6‐month survival was developed by Cox proportional hazards modeling with inverse probability weighting for surgery treatment and was internally validated by the bootstrapping method. This model was externally validated in an independent prospective registry ( ICE ‐ PLUS , 2008–2012, n=1197). The 6‐month mortality was 971 of 4049 (24.0%) in the ICE ‐ PCS cohort and 342 of 1197 (28.6%) in the ICE ‐ PLUS cohort. Surgery during the index hospitalization was performed in 48.1% and 54.0% of the cohorts, respectively. In the derivation model, variables related to host factors (age, dialysis), IE characteristics (prosthetic or nosocomial IE , causative organism, left‐sided valve vegetation), and IE complications (severe heart failure, stroke, paravalvular complication, and persistent bacteremia) were independently associated with 6‐month mortality, and surgery was associated with a lower risk of mortality (Harrell's C statistic 0.715). In the validation model, these variables had similar hazard ratios (Harrell's C statistic 0.682), with a similar, independent benefit of surgery (hazard ratio 0.74, 95% CI 0.62–0.89). A simplified risk model was developed by weight adjustment of these variables. Conclusions Six‐month mortality after IE is ≈25% and is predicted by host factors, IE characteristics, and IE complications. Surgery during the index hospitalization is associated with lower mortality but is performed less frequently in the highest risk patients. A simplified risk model may be used to identify specific risk subgroups in IE .

Published
2016
Full Text
View/download PDF

3. Formes et fonctions du théâtre dans le théâtre dans l'oeuvre dramatique de Dario Fo et Franca Rame

Author

Urbani, Brigitte, Centre Aixois d'Etudes Romanes (CAER), Aix Marseille Université (AMU), Paolo Grossi et Perette-Cécile Buffaria, Perette-Cécile Buffaria, and Paolo Grossi

Subjects
métathéâtralité, [SHS.LITT]Humanities and Social Sciences/Literature, Dario Fo, théâtre dans le théâtre, Franca Rame
Abstract

International audience; Si l’on considère que le théâtre dans le théâtre est la mise en scène d’acteurs-spectateurs regardant eux-mêmes une pièce de théâtre ou occupés à la réalisation d’un spectacle, trois œuvres seulement semblent répondre à cette définition dans la production de Dario Fo et de Franca Rame. Mais si l’on considère comme métathéâtrale toute pièce contenant une petite comédie à laquelle assistent des personnages, le corpus s’agrandit. Si l’on englobe aussi les comédies où un mince cadre enchâsse une action principale développée selon l’expédient du rêve, il s’étend encore. Si l’on prend également en considération les spectacles à l’intérieur desquels les personnages jouent la comédie pour en éduquer ou en tromper d’autres, la vague devient déferlante. Shakespeare, l’une des principales références de Fo, a abondamment pratiqué la métathéâtralité, de même que bien des auteurs européens des XVIIe, XVIIIe et XXe siècles.Les formes de théâtre dans le théâtre dans l’œuvre dramatique de Dario Fo et Franca Rame sont multiples, c’est pourquoi nous considérerons aussi bien le théâtre dans le théâtre au sens strict du terme (pièce à l’intérieur de la pièce) que les éléments de métathéâtralité (discours sur le théâtre), la distanciation, la mise en abyme, voire les jeux de rôle : autant de techniques au service du théâtre et de sa fonction tels que les entend le couple d’auteurs-acteurs.

Published
2010

4. Corpi e tempi morti nella poesia di Andrea Zanzotto

Author

Bongiorno, Giorgia, Littératures, Imaginaire, Sociétés (LIS), Université de Lorraine (UL), Bongiorno, Giorgia, Donatella Favaretto, Laura Toppan, Paolo Grossi, and UL, Lis

Subjects
[SHS.LITT] Humanities and Social Sciences/Literature, Andrea (1921-2011) -- Critique et interprétation, [SHS.LITT]Humanities and Social Sciences/Literature, Zanzotto, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2014

5. Narrazione e ibridazione dei generi nella 'Vita' di Athanasius Kircher

Author

Totaro , Giunia, Lettres, arts du spectacle, langues romanes (LASLAR), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Lettres, arts du spectacle, langues romanes ( LASLAR ), Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ), and Silvia Fabrizio-Costa, Paolo Grossi, Laura Sannia Nowé

Subjects
Genres littéraires, Latino, Roma, [SHS.LITT]Humanities and Social Sciences/Literature, Conte de fées, Gesuiti, novella, Rome, Ecriture de soi, Compagnia di Gesù, Autobiographie, Libretto, Fiaba, Chi soffre speri, XVI secolo, Histoire, Clément IX, Baroque, Jésuite, Boccace, Storia, XVIe siècle, nouvelle, Livret, Athanasius Kircher, Ibridazione, Agnolella, Autobiografia, Compagnie de Jésus, Nouvelle, Mythe, Pietro Boccamazza, "Chi soffre speri", Narration, Hybridation, Barocco, Boccaccio, Scrittura autobiografica, [ SHS.LITT ] Humanities and Social Sciences/Literature, écriture de soi, Latin, "Décameron", Clemente IX, Mito, Generi letterari, Narrazione, Novella, Giulio Rospigliosi, Décameron
Abstract

S. Fabrizio-Costa, P. Grossi e L. Sannia Nowé (ed). Edition numérique : ISBN 978-3-0352-0173-4 - DOI de l'ouvrage : https://doi.org/10.3726/978-3-0352-0173-4.; International audience; Comme on le sait, la notion de genre est une convention assez floue ; d'ailleurs sur n'importe quel ouvrage, considéré comme appartenant à un genre littéraire, d'autres genres agissent de façon plus ou moins apparente. Cela est particulièrement vrai pour l'autobiographie : c'est le cas de la "Vita" d'Athanasius Kircher, dont le récit révèle les influences les plus disparates. Cette contribution essaie de montrer comment la narration d'un épisode de la "Vita" s'inspire de la nouvelle et puise ses matériaux dans un chef-d'œuvre de la tradition italienne, le "Décameron" de Boccace, dont l'exploitation passe par un livret d'opéra du futur Clément IX, un ouvrage appartenant lui-même à un genre de frontière.; Com'è noto, la nozione di genere letterario è una convenzione piuttosto nebulosa; d'altraparte su qualsiasi opera che si consideri appartenente ad un genere agiscono in modo piùo meno evidente altri generi. Tutto questo è vero in modo particulare per l'autobiografia:cosi è per la "Vita" di Athanasius Kircher, la quale rivela le influenze più disparate. Questocontributo cerca di mostrare come la narrazione di un episodio della "Vita" si ispiri allanovella, ed attinga la propria materia da un capolavoro della tradizione italiana, il"Decameron" di Boccaccio, la cui fruizione passa attraverso un libretto musicale del futuroClemente IX, opera anch'essa appartenente ad un genere di frontiera.

Published
2012

6. Benvenuto Cellini et ses commanditaires

Author

Bianchini, Michelle, des publications scientifiques, Base, Pérette-Cécile Buffaria, and Paolo Grossi

Subjects
[SHS.ART] Humanities and Social Sciences/Art and art history, ComputingMilieux_MISCELLANEOUS
Published
2009

7. Benvenuto Cellini et ses commanditaires: entre liberté et aliénation

Author

Bianchini, Michelle, Langues, Littératures, Arts et Cultures des Suds (LLACS), Université Paul-Valéry - Montpellier 3 (UPVM), Pérette-Cécile Buffaria, and Paolo Grossi

Subjects
[SHS.ART]Humanities and Social Sciences/Art and art history, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2009

8. « Divino Michelangelo, Cellini diabolico : la Vita come mitizzazione capovolta »

Author

Orsino, Margherita, Orsino, Margherita, Pérette Cécile Buffaria, Paolo Grossi, Centre d'études ibériques et ibéro-américaines - cultures romanes et amérindiennes (CEIIBA), Université Toulouse - Jean Jaurès (UT2J), and Istituto Italiano di Cultura

Subjects
[SHS.LITT] Humanities and Social Sciences/Literature, artiste divin, [SHS.LITT]Humanities and Social Sciences/Literature, artiste diabolique, Cellini, Michelangelo Buonarroti / Michel-Ange, [SHS.ART] Humanities and Social Sciences/Art and art history, [SHS.ART]Humanities and Social Sciences/Art and art history, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results